title: Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
authors.affiliation: Department of Nephrology, University Hospital, Cologne, FRG.
authors.forename: M
authors.initials: M
authors.lastname: Pollok
authors.forename: J
authors.initials: J
authors.lastname: Bommer
authors.forename: H J
authors.initials: HJ
authors.lastname: Gurland
authors.forename: K M
authors.initials: KM
authors.lastname: Koch
authors.forename: W
authors.initials: W
authors.lastname: Schoeppe
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
authors.forename: C A
authors.initials: CA
authors.lastname: Baldamus
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011897:Random Allocation; D006435:Renal Dialysis; D012156:Reticulocytes; D013927:Thrombosis / Q000139:chemically induced
chemical_list: D004921:Erythropoietin